Russian biopharmaceutical company Promomed has launched a clinical trial to evaluate the efficacy and safety of tirzepatide for the treatment of obesity and overweight in adolescents aged 12-17, according to the State Register of Medicines. The drug is an analogue of Mounjaro, manufactured by U.S. pharmaceutical giant Eli Lilly. As GxP News reported, the study is currently in the active patient recruitment phase.
According to the state register, the company is investigating a solution for subcutaneous administration in dosages of 2.5 mg/dose, 5 mg/dose, 7.5 mg/dose, 10 mg/dose, 12.5 mg/dose, and 15 mg/dose. The trials will run through the end of June 2028 across 18 medical institutions in Moscow, St. Petersburg, Smolensk, Yekaterinburg, Voronezh, Novosibirsk, and other cities. A total of 264 adolescents are expected to participate in the clinical trial.
At present, only liraglutide – marketed under the brand name Enligria – is available in Russia for treating adolescent patients, Promomed’s press service reported.
“We understand that the evidence base is particularly critical for pediatric drugs, which is precisely why we decided to initiate our own study of tirzepatide in the form of the preservative-free drug Tirzetta for adolescents,” representatives of the Russian company emphasized.
Previously, in December 2025, another Russian company, Geropharm, announced plans to conduct studies evaluating the efficacy and safety of the drug in adolescents.